Indian J Pharm Close
 

Figure 2 :(A) Fast binding nature of sitagliptin. Inhibition studies performed by the addition of enzyme to pre-incubated mixture of substrate and various concentrations of sitagliptin (0, 5, 12.5, 25, 50 and 125 nM fi nal); (B) Sitagliptin inhibition is reversible. The human recombinant DPP-IV (10 ng) pre-incubated without (VC) or with sitagliptin (500 nM) or vildagliptin (50 nM) diluted more than 100-fold into 0.5 mM H-Gly-Pro-AMC and the DPP-IV activity measured. Both A and B represent one experiment (n=3).

Figure 2 :(A) Fast binding nature of sitagliptin. Inhibition studies performed by the addition of enzyme to pre-incubated mixture of substrate and various concentrations of sitagliptin (0, 5, 12.5, 25, 50 and 125 nM fi nal); (B) Sitagliptin inhibition is reversible. The human recombinant DPP-IV (10 ng) pre-incubated without (VC) or with sitagliptin (500 nM) or vildagliptin (50 nM) diluted more than 100-fold into 0.5 mM H-Gly-Pro-AMC and the DPP-IV activity measured. Both A and B represent one experiment (n=3).